SEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs
Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/8/2024 | $8.00 | Buy | Ladenburg Thalmann |
MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 2 - TodayFebruary 19, 2025 Replay Day 1 here:https://emerginggrowt
MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1February 18, 2025 9:30Virtual Lobby opens.Register for the Conference. If you already registered, go back to the
February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025. The live, interactive online event will give existing shareh
Ladenburg Thalmann initiated coverage of Biodexa Pharmaceuticals PLC with a rating of Buy and set a new price target of $8.00
SCHEDULE 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists
Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, is pleased to announce the appointment of Ann Merchant to the Board of Directors of the Company as Non-executive Director with effect from 31 December 2023. Since 2018, Ann Merchant has served as Vice President for MorphoSys, and currently as Head of Global Supply Chain and Externa
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)